H.R.5371: CONTINUING APPROPRIATIONS, ARGICULTURE, LEGISLATIVE BRANCH, MILITARY CONSTRUCTION AND VETERANS AFFAIRS, AND EXTENSIONS ACT, 2026; PROVISIONS RELATED TO JOINT EXPLANTATORY STATEMENT, DIV. B
Literal federal measure citations: H.R.5371
2025 · 4th Quarter (Oct 1 - Dec 31)
BIOMARIN PHARMACEUTICAL INC.
Filed by BIOMARIN PHARMACEUTICAL INC..
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 21, 2026
- Income
- Not reported
- Expenses
- $390,000.00
- Registrant
- BIOMARIN PHARMACEUTICAL INC.
- Filing UUID
- 145ae244-f2d7-48aa-9a67-2d78ffb338f1
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.